BRAXF - Braxia Scientific awarded Government of Canada funding for Bipolar Depression trial

Braxia Scientific (BRAXF) has been awarded funding by the Canadian Institute of Health Research ((CIHR)), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression.The fully funded study will investigate the use, safety and efficacy of repeated doses of intravenous ((IV)) Ketamine in patients with the condition.The trial, in collaboration with Toronto's University Health Network ((UHN)), will include 100 participants across two sites, and will be lead by Braxia's Chief Medical and Science Officer, Joshua Rosenblat.

For further details see:

Braxia Scientific awarded Government of Canada funding for Bipolar Depression trial